Real-world use of immune checkpoint inhibitors in advanced or recurrent endometrial cancer.
Sarah P HuepenbeckerLarissa A MeyerMiranda CraftJohn K ChanChristopher CraggsPeter LambertYvonne G LinPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024)
In an observational retrospective real-world database study, immune checkpoint inhibitors were used in 14.7% of patients with advanced or recurrent endometrial cancer across multiple lines of treatment, including after initial immune checkpoint inhibitor treatment.